AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
indoprofen 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anti-inflammatory agents, ibuprofen derivatives | 1442 | 31842-01-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A drug that has analgesic and anti-inflammatory properties. Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p21)
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.12 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.65 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.11 hours | Lombardo F, Berellini G, Obach RS |
| BA (Bioavailability) | 100 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -0.307 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 3.917 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 60.256 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.198 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 7.570 | % | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 12.500 | % | High | 1 |
| herg | hERG pIC50 | 4.416 | pIC50 | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 1.365 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.069 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 4.780 | % | High | 1 |
| kinase-safety-class | ACVR2B,AXL,BTK,CDK5,CDK9,EIF2AK3,ERBB2,GRK2,MAPK7,PDK1,PDK2,PDK4,PIK3CB,PRKDC,TEK | 15 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,MAP2K6 | 4 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 7.762 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 6.516 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 15.970 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 2.218 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 9.360 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.667 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 88.380 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 3.250 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 963.829 | uM | High | 1 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | M01AE10 | MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Propionic acid derivatives |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D000893 | Anti-Inflammatory Agents |
| MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D016861 | Cyclooxygenase Inhibitors |
| MeSH PA | D018501 | Antirheumatic Agents |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory drug |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:35544 | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor |
Related Drugs by ATC class:
M01AE Propionic acid derivatives 21 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.08 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histone deacetylase 6 | Enzyme | IC50 | 6.29 | CHEMBL | |||||
| Pyruvate kinase PKM | Enzyme | IC50 | 4.68 | CHEMBL | |||||
| Fatty acid-binding protein, liver | Cytosolic other | Ki | 5.90 | CHEMBL | |||||
| Luciferin 4-monooxygenase | Enzyme | IC50 | 6.70 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D04530 | KEGG_DRUG |
| C0021251 | UMLSCUI |
| CHEBI:76162 | CHEBI |
| CHEMBL15870 | ChEMBL_ID |
| DB08951 | DRUGBANK_ID |
| D007216 | MESH_DESCRIPTOR_UI |
| 3718 | PUBCHEM_CID |
| 3689 | INN_ID |
| CPE46ZU14N | UNII |
| 002385 | NDDF |
| CPE46ZU14N | INXIGHT DRUGS |
Pharmaceutical products:
None